Entinostat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Entinostat
Accession Number
DB11841
Type
Small Molecule
Groups
Investigational
Description

Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.

Structure
Thumb
Synonyms
Not Available
External IDs
MS-27-275 / MS-275-27 / SNDX-275
Categories
UNII
1ZNY4FKK9H
CAS number
209783-80-2
Weight
Average: 376.416
Monoisotopic: 376.15354052
Chemical Formula
C21H20N4O3
InChI Key
INVTYAOGFAGBOE-UHFFFAOYSA-N
InChI
InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)
IUPAC Name
(pyridin-3-yl)methyl N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate
SMILES
NC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Entinostat.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Entinostat.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Entinostat.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Entinostat.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Entinostat.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Entinostat.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Entinostat.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Entinostat.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Entinostat.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Entinostat.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Entinostat.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Entinostat.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Entinostat.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Entinostat.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Entinostat.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Entinostat.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Entinostat.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Entinostat.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Entinostat.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
4261
PubChem Substance
347828185
ChemSpider
4111
BindingDB
19410
ChEBI
132082
ChEMBL
CHEMBL27759

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentHER2/Neu Positive / Invasive Breast Carcinoma / Recurrent Breast Carcinoma / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v71
1CompletedOtherDrug Interactions / Healthy Volunteers1
1CompletedTreatmentAcute Leukemias of Ambiguous Lineage / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
1CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentCancer, Breast / Estrogen Receptor Breast Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1CompletedTreatmentCancers1
1CompletedTreatmentLeukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1Not Yet RecruitingNot AvailableHealthy Volunteers / Human Volunteers / Normal Volunteers / Volunteers1
1RecruitingOtherHealthy Volunteers / Human Volunteers / Normal Volunteers / Volunteers1
1RecruitingOtherHealthy Volunteers / Impaired Renal Function1
1RecruitingTreatmentBreast Adenocarcinoma / HER2/Neu Negative / Invasive Breast Carcinoma / Metastatic Malignant Solid Neoplasm / Metastatic Solid Neoplasm / Recurrent Breast Carcinoma / Solid Neoplasms / Stage III Breast Cancer / Stage III Breast Cancer AJCC V7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Unresectable Solid Neoplasm1
1RecruitingTreatmentBreast Diseases / Chronic Lung Diseases / Digestive System Neoplasms / Endocrine Gland Neoplasms / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm, Bronchial / Neoplasms / Neoplasms by Histologic Type / Neoplasms, Breast / Neoplasms, Glandular and Epithelial / Neoplasms, Lung / Renal Neoplasms / Respiratory Tract Neoplasms / Thoracic Neoplasms / Tumors, Solid1
1RecruitingTreatmentBreast Diseases / Chronic Lung Diseases / Digestive System Neoplasms / Endocrine Gland Neoplasms / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm, Bronchial / Neoplasms / Neoplasms by Histologic Type / Neoplasms, Glandular and Epithelial / Neoplasms, Lung / Renal Neoplasms / Respiratory Tract Neoplasms / Thoracic Neoplasms / Tumors, Solid1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentCancer, Breast / Estrogen Receptor Positive Breast Cancer1
1RecruitingTreatmentChildhood Brain Stem Neoplasm / Childhood Lymphoma / Childhood Solid Neoplasm / Pineal Region Neoplasm / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Childhood Visual Pathway Glioma / Refractory Central Nervous System Neoplasm1
1RecruitingTreatmentMyelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes1
1TerminatedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Blastic Phase Chronic Myelogenous Leukemia / Recurrent Adult Acute Myeloid Leukemia / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentStage IA Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer1
1WithdrawnNot AvailableCancer, Breast1
1, 2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Metastatic Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2Active Not RecruitingTreatmentMetastatic Cancers / Renal Cancers1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2Not Yet RecruitingTreatmentColorectal Cancers1
1, 2RecruitingTreatmentCancer, Breast1
1, 2RecruitingTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Mismatch Repair-Proficient Colorectal Cancer1
1, 2TerminatedTreatmentPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2CompletedTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentBreast Cancer, Estrogen Receptor-Positive / Cancer, Breast / ER+ Breast Cancer / Estrogen Receptor-Positive Breast Cancer1
2CompletedTreatmentER+ Breast Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2Not Yet RecruitingTreatmentMetastatic Uveal Melanoma1
2Not Yet RecruitingTreatmentNeuroendocrine Tumors1
2Not Yet RecruitingTreatmentPreviously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreactic Cancer1
2RecruitingTreatmentAdvanced or Recurrent Breast Cancer1
2RecruitingTreatmentGrade 1 Endometrial Endometrioid Adenocarcinoma / Grade 2 Endometrial Endometrioid Adenocarcinoma / Grade 3 Endometrial Endometrioid Adenocarcinoma / Uterine Corpus Adenosarcoma1
2RecruitingTreatmentMalignant Lymphomas / Refractory / Relapses1
2RecruitingTreatmentNon-Small Lung Cancer, Epigenetic Therapy1
2TerminatedTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentStage IA Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma1
2WithdrawnTreatmentCancer, Breast1
3RecruitingTreatmentEstrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00574 mg/mLALOGPS
logP2.07ALOGPS
logP2.31ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.54ChemAxon
pKa (Strongest Basic)4.74ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area106.34 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity108.29 m3·mol-1ChemAxon
Polarizability39.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
Benzamides / Benzoyl derivatives / Aniline and substituted anilines / Pyridines and derivatives / Heteroaromatic compounds / Carbamate esters / Secondary carboxylic acid amides / Organic carbonic acids and derivatives / Azacyclic compounds / Primary amines
show 4 more
Substituents
Benzanilide / Benzamide / Benzoic acid or derivatives / Benzoyl / Aniline or substituted anilines / Pyridine / Heteroaromatic compound / Carbamic acid ester / Amino acid or derivatives / Carboxamide group
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:53 / Updated on November 09, 2017 04:58